» Articles » PMID: 34239263

Non-cirrhotic Hepatocellular Carcinoma in Chronic Viral Hepatitis: Current Insights and Advancements

Overview
Specialty Gastroenterology
Date 2021 Jul 9
PMID 34239263
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Primary liver cancers carry significant morbidity and mortality. Hepatocellular carcinoma (HCC) develops within the hepatic parenchyma and is the most common malignancy originating from the liver. Although 80% of HCCs develop within background cirrhosis, 20% may arise in a non-cirrhotic milieu and are referred to non-cirrhotic-HCC (NCHCC). NCHCC is often diagnosed late due to lack of surveillance. In addition, the rising prevalence of non-alcoholic fatty liver disease and diabetes mellitus have increased the risk of developing HCC on non-cirrhotic patients. Viral infections such as chronic Hepatitis B and less often chronic hepatitis C with advance fibrosis are associated with NCHCC. NCHCC individuals may have Hepatitis B core antibodies and occult HBV infection, signifying the role of Hepatitis B infection in NCHCC. Given the effectiveness of current antiviral therapies, surgical techniques and locoregional treatment options, nowadays such patients have more options and potential for cure. However, these lesions need early identification with diagnostic models and multiple surveillance strategies to improve overall outcomes. Better understanding of the NCHCC risk factors, tumorigenesis, diagnostic tools and treatment options are critical to improving prognosis and overall outcomes on these patients. In this review, we aim to discuss NCHCC epidemiology, risk factors, and pathogenesis, and elaborate on NCHCC diagnosis and treatment strategies.

Citing Articles

Assessing the Causal Effect of Circulating Protein-To-Protein Ratio on the Risk of Morbidity of Hepatocellular Carcinoma.

Yue Q, Li X, Wan X, Lin X, Li Y, Zhang M Cancer Med. 2025; 14(1):e70570.

PMID: 39778021 PMC: 11705445. DOI: 10.1002/cam4.70570.


Role of Imaging in Screening for Hepatocellular Carcinoma.

Kazi I, Jahagirdar V, Kabir B, Syed A, Kabir A, Perisetti A Cancers (Basel). 2024; 16(19).

PMID: 39410020 PMC: 11476228. DOI: 10.3390/cancers16193400.


Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma.

Kohla M, Ashour R, Taha H, El-Abd O, Osman M, Abozeid M BMC Gastroenterol. 2024; 24(1):318.

PMID: 39294585 PMC: 11409554. DOI: 10.1186/s12876-024-03387-5.


HCC in patients without cirrhosis: A review.

Aryan M, Ruli T, Shoreibah M Clin Liver Dis (Hoboken). 2024; 23(1):e0224.

PMID: 38872781 PMC: 11168850. DOI: 10.1097/CLD.0000000000000224.


Plasticity, heterogeneity, and multifunctionality of hepatic stellate cells in liver pathophysiology.

Du K, Jun J, Dutta R, Diehl A Hepatol Commun. 2024; 8(5).

PMID: 38619452 PMC: 11019831. DOI: 10.1097/HC9.0000000000000411.


References
1.
Sureau C, Negro F . The hepatitis delta virus: Replication and pathogenesis. J Hepatol. 2016; 64(1 Suppl):S102-S116. DOI: 10.1016/j.jhep.2016.02.013. View

2.
Huo T, Ho S, Liu P . Changing faces of hepatocellular carcinoma: East vs West. Liver Int. 2020; 41(6):1430-1431. DOI: 10.1111/liv.14753. View

3.
Smalley S, MOERTEL C, Hilton J, Weiland L, Weiand H, ADSON M . Hepatoma in the noncirrhotic liver. Cancer. 1988; 62(7):1414-24. DOI: 10.1002/1097-0142(19881001)62:7<1414::aid-cncr2820620729>3.0.co;2-7. View

4.
Guniganti P, Kierans A . PET/MRI of the hepatobiliary system: Review of techniques and applications. Clin Imaging. 2020; 71:160-169. DOI: 10.1016/j.clinimag.2020.10.056. View

5.
Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H . Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005; 40(2):148-56. DOI: 10.1007/s00535-004-1519-2. View